Contrafect Corp. (NASDAQ: CFRX): Initiating Coverage With Buy Rating And Price Target=$7

CFRX

Contrafect (CFRX) is a Yonkers, NY based emerging biopharmaceutical company that was founded in 2008. The company's key pipeline molecule is based on its proprietary lysin antibody platform.

(Contrafect, common stock price chart. Source: Bloomberg)

Technology:

Contrafect (CFRX) is a Yonkers, NY based emerging biopharmaceutical company that was founded in 2008. The company's key pipeline molecule is based on its proprietary lysin antibody platform.

(Contrafect, common stock price chart. Source: Bloomberg)

Technology:

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics